You are viewing the site in preview mode
Skip to main content
|
Model (reference)
|
MMR index [[25]]
|
MsPath [[19],[23]]
|
PREDICT [[22]]
|
MSI probability score [[21]]
|
RERtest6 [[20],[24]]
|
|---|
|
No. of variables
|
7
|
6
|
6
|
7
|
6
|
|
Sex
|
Female
|
-
|
-
|
-
|
-
|
|
Age (years)
|
≥60
|
<50
|
<50
|
<50
|
-
|
|
Tumor location
|
Proximal
|
Proximal
|
Proximal
|
Proximal
|
Proximal
|
|
Growth pattern
|
Expanding
|
-
|
-
|
-
|
Expanding
|
|
Dirty necrosis
|
Lack of
|
-
|
-
|
Lack of
|
-
|
|
Mucinous/signet-ring components
|
≥10%
|
≥50% (including medullary carcinoma)
|
Any component
|
Any component
|
Amount in %
|
|
Solid component
| |
-
|
-
|
-
|
Amount in %
|
|
TIL
|
≥7 TIL/10 HPF
|
≥5 TIL/HPF (10 HPFs searched)
|
≥ 5TIL/HPF (10 HPF searched)
|
≥2 TIL/mean of 5 HPF
|
≥4TIL/HPF
|
|
Differentiation
|
-
|
Poorly differentiated
|
-
|
Well or poorly differentiated
|
-
|
|
Crohn-like reaction
|
-
|
≥4 nodules/LPF
|
-
|
≥3 nodules/section
|
≥3 nodules/LPF
|
|
Peritumoral lymphocytic reaction
|
-
|
-
|
Banding of lymphocytes beyond advancing edge
|
-
|
-
|
|
Increased stromal plasma cells
|
-
|
-
|
>25% plasma cells/stromal immune cells
|
-
|
-
|
|
Scoring system
|
No score, 7-factor index, cut-off ≥4
|
Score: cut-off ≥1
|
Score: cut-off ≥2.5; “Simplified PREDICT”: no score, ≥2 features present
|
Score: cut-off ≥1 or ≥1.5
|
Score: cut-off <0.8
|
|
Sensitivity
|
92.3% (4 features of 7)
|
93%
|
96.9% (score ≥2.5)
|
92% (score 1)
|
78.0%
|
|
Specificity
|
75.3% (4 features of 7)
|
55%
|
76.6% (score ≥2.5)
|
46% (score 1)
|
93.4%
|
|
Method applied for determination of MMR deficiency
|
IHC (4 markers), BRAF mutation
|
MSI (10 markers) and IHC (4 markers); validation study: MSI (5 markers) and IHC (MLH1, MSH2), BRAF mutation
|
MSI (5 markers); validation cohort only 1 marker if age ≥75 years
|
MSI (4 markers)
|
MSI (11 markers)
|
-
Abbreviations: HPF high-power field, IHC immunohistochemistry, LPF low-power field, MMR mismatch repair, MSI microsatellite instability, TIL tumor-infiltrating lymphocytes.
